Company research
Medirom Healthcare Technologies Inc.
CIK 1819704Updated Nov 19, 2026
MRM price & chart
Loading TradingView…
NASDAQ:MRM on TradingView ↗About the company
MEDIROM, a holistic healthcare company, operates 292 (as of Dec 31, 2025) relaxation salons across Japan, Re. Ra. Ku® being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called “Lav®”, which is developed by the Company. MEDIROM also entered the device business in 2020 and has developed a smart tracker “MOTHER Bracelet®”. In 2023, MEDIROM launched REMONY®, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM hopes that its diverse health-related product and service offerings will help it collect and manage healthcare data from users and customers and enable it to become a leader in big data in the healthcare industry. For more information, visit https://medirom.co.jp/en.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Financials
FY 2024 · JPYSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| AssetsJPY | 7,995,808,000Source | 5,827,039,000Source | 8,090,671,000Source | 6,849,189,000Source | 6,747,346,000Source | 5,753,061,000Source |
| Property, Plant and Equipment, NetJPY | 377,585,000Source | — | 435,659,000Source | 451,498,000Source | 424,288,000Source | 424,996,000Source |
| GoodwillJPY | 375,383,000Source | — | 389,131,000Source | 484,564,000Source | 539,490,000Source | 600,329,000Source |
| Intangible Assets, Net (Excluding Goodwill)JPY | — | — | 1,139,297,000Source | 920,700,000Source | 403,674,000Source | 391,038,000Source |
| Current assets: | ||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,663,000Source | — | 2,093,000Source | 755,000Source | 4,593,000Source | 370,617,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentJPY | 187,968,000Source | — | 1,355,489,000Source | 621,867,000Source | 534,686,000Source | 312,302,000Source |
| Inventory, NetJPY | 175,152,000Source | — | 151,637,000Source | 139,982,000Source | 114,109,000Source | 18,703,000Source |
| Assets, CurrentJPY | 1,213,650,000Source | — | 2,706,062,000Source | 1,758,704,000Source | 2,363,211,000Source | 1,382,302,000Source |
| Prepaid Expense and Other Assets, CurrentJPY | 335,554,000Source | — | 217,174,000Source | 257,932,000Source | 292,643,000Source | 111,166,000Source |
| Operating Lease, Right-of-Use AssetJPY | 1,886,062,000Source | — | 2,073,763,000Source | 2,089,402,000Source | 1,955,354,000Source | 1,824,095,000Source |
| Other Assets, NoncurrentJPY | 71,622,000Source | — | 80,571,000Source | 16,655,000Source | 13,666,000Source | 107,224,000Source |
| LIABILITIES AND EQUITY | ||||||
| LiabilitiesJPY | 7,497,637,000Source | — | 6,902,613,000Source | 6,633,228,000Source | 6,806,724,000Source | 5,961,404,000Source |
| Stockholders’ equity: | ||||||
| Retained Earnings (Accumulated Deficit)JPY | -461,431,000Source | — | 229,040,000Source | 80,277,000Source | -2,545,068,000Source | -2,694,033,000Source |
| Stockholders' Equity Attributable to ParentJPY | 242,797,000Source | — | 933,268,000Source | 210,879,000Source | -59,378,000Source | -208,343,000Source |
| Additional Paid in Capital, Common StockJPY | 354,605,000Source | — | 354,605,000Source | 113,602,000Source | 1,265,456,000Source | 1,265,456,000Source |
| Liabilities and EquityJPY | 7,995,808,000Source | — | 8,090,671,000Source | 6,849,189,000Source | 6,747,346,000Source | 5,753,061,000Source |
| Current liabilities: | ||||||
| Liabilities, CurrentJPY | 4,987,046,000Source | — | 4,181,481,000Source | 3,560,593,000Source | 3,641,967,000Source | 3,196,473,000Source |
| Operating Lease, Liability, CurrentJPY | 795,728,000Source | — | 792,781,000Source | 763,422,000Source | 769,769,000Source | 755,219,000Source |
| Accounts Payable, CurrentJPY | 1,418,839,000Source | — | 1,014,205,000Source | 137,697,000Source | 207,581,000Source | 230,899,000Source |
| Operating Lease, Liability, NoncurrentJPY | 1,151,939,000Source | — | 1,287,509,000Source | 1,334,630,000Source | 1,212,629,000Source | 1,128,737,000Source |
| Other Liabilities, NoncurrentJPY | 14,747,000Source | — | 17,424,000Source | 9,801,000Source | 30,422,000Source | 25,176,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestJPY | 55,214,000Source | — | 54,630,000Source | 5,082,000Source | — | — |
| Additional Financial Items | ||||||
| Accrued Liabilities, CurrentJPY | 461,415,000Source | — | 325,544,000Source | 1,261,909,000Source | 1,383,579,000Source | 865,865,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | — | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesJPY | 627,907,000Source | — | 620,813,000Source | 100,415,000Source | 99,168,000Source | 162,252,000Source |
| Long-term Debt, Excluding Current MaturitiesJPY | 720,459,000Source | — | 764,200,000Source | 1,050,802,000Source | 1,149,769,000Source | 746,588,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountJPY | 200,160,000Source | — | 200,160,000Source | — | 0Source | 148,000,000Source |
| Short-term InvestmentsJPY | 6,156,000Source | — | 6,156,000Source | 26,502,000Source | 26,500,000Source | 26,526,000Source |
cash flow · annual statements
| Line item | Q2 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestJPY | — | 138,191,000Source | 115,049,000Source | 148,965,000Source | -990,731,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation, Depletion and AmortizationJPY | — | 290,038,000Source | 252,595,000Source | 184,056,000Source | 126,243,000Source |
| Share-based Payment Arrangement, Noncash ExpenseJPY | — | — | — | — | 196,853,000Source |
| Changes in operating assets and liabilities: | |||||
| Increase (Decrease) in Accounts ReceivableJPY | — | -339,120,000Source | -580,681,000Source | 222,384,000Source | 37,024,000Source |
| Increase (Decrease) in InventoriesJPY | — | 10,612,000Source | 25,873,000Source | 95,406,000Source | 2,441,000Source |
| Increase (Decrease) in Accounts PayableJPY | — | 876,508,000Source | -69,884,000Source | -23,318,000Source | 58,437,000Source |
| Deferred Income Tax Expense (Benefit)JPY | — | -188,706,000Source | -101,636,000Source | — | 551,483,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesJPY | — | -1,331,681,000Source | -631,737,000Source | -685,697,000Source | -557,231,000Source |
| Cash flows from investing activities: | |||||
| Payments to Acquire Businesses, Net of Cash AcquiredJPY | — | 21,348,000Source | — | 148,000,000Source | 375,757,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesJPY | — | 361,393,000Source | -328,576,000Source | 580,437,000Source | -83,936,000Source |
| Payments to Acquire Property, Plant, and EquipmentJPY | — | 71,408,000Source | 135,840,000Source | 120,740,000Source | 95,651,000Source |
| Cash flows from financing activities: | |||||
| Net Cash Provided by (Used in) Financing ActivitiesJPY | — | 1,193,340,000Source | 461,206,000Source | 340,097,000Source | -427,949,000Source |
| Repayments of Long-term DebtJPY | — | 96,708,000Source | 99,084,000Source | 45,270,000Source | 251,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectJPY | — | 223,052,000Source | -499,107,000Source | 234,837,000Source | -1,069,116,000Source |
| Supplemental disclosure of cash flow information: | |||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesJPY | — | 47,558,000Source | 34,575,000Source | 7,535,000Source | 10,865,000Source |
| Income Taxes Paid, NetJPY | — | 12,777,000Source | 52,105,000Source | 30,809,000Source | 45,505,000Source |
| Additional Financial Items | |||||
| Amortization of Intangible AssetsJPY | — | 182,413,000Source | 145,555,000Source | 85,918,000Source | 45,780,000Source |
| Asset Retirement Obligation, Accretion ExpenseJPY | — | 3,781,000Source | 3,095,000Source | 24,424,000Source | 2,172,000Source |
| DepreciationJPY | — | 100,462,000Source | 107,040,000Source | 82,795,000Source | 80,463,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxJPY | — | 18,121,000Source | 26,825,000Source | 14,830,000Source | 14,992,000Source |
| Gain (Loss) on Disposition of AssetsJPY | — | 40,631,000Source | 413,678,000Source | — | — |
| Gain (Loss) on Disposition of BusinessJPY | — | — | — | — | -2,692,000Source |
| GoodwillJPY | 375,383,000Source | 389,131,000Source | 484,564,000Source | 539,490,000Source | 600,329,000Source |
| Goodwill, Impairment LossJPY | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)JPY | — | — | 0Source | 0Source | — |
| Income Tax Expense (Benefit)JPY | — | -90,478,000Source | -94,427,000Source | 30,809,000Source | 576,250,000Source |
| InterestExpenseNonoperatingJPY | — | 49,745,000Source | — | — | — |
| Investment Income, InterestJPY | — | 8,000Source | 1,111,000Source | 6,072,000Source | 839,000Source |
| Net Income (Loss) Attributable to ParentJPY | — | 148,763,000Source | 115,404,000Source | 148,965,000Source | -990,731,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestJPY | — | — | -355,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicJPY | — | — | — | 148,965,000Source | -990,731,000Source |
| Nonoperating Income (Expense)JPY | — | 65,815,000Source | 412,201,000Source | 82,807,000Source | 56,106,000Source |
| Operating Lease, ExpenseJPY | — | 89,120,000Source | — | — | — |
| Operating Lease, Impairment LossJPY | — | — | — | — | 20,979,000Source |
| Other Nonoperating Income (Expense)JPY | — | 42,943,000Source | -13,923,000Source | 51,078,000Source | 24,377,000Source |
| Proceeds from Issuance of Long-term DebtJPY | — | 300,000,000Source | — | 547,619,000Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueJPY | 8,299,134,000Source | 6,827,943,000Source | 6,954,057,000Source | 5,409,825,000Source |
| Cost of Goods and Services Sold | —Source | — | — | — |
| Selling, General and Administrative ExpenseJPY | 2,241,515,000Source | 1,960,447,000Source | 1,805,490,000Source | 1,822,787,000Source |
| Operating Income (Loss)JPY | -18,102,000Source | -391,579,000Source | 96,967,000Source | -470,587,000Source |
| Other Nonoperating Income (Expense)JPY | 42,943,000Source | -13,923,000Source | 51,078,000Source | 24,377,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestJPY | 47,713,000Source | 20,622,000Source | 179,774,000Source | -414,481,000Source |
| Income Tax Expense (Benefit)JPY | -90,478,000Source | -94,427,000Source | 30,809,000Source | 576,250,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestJPY | — | -355,000Source | — | — |
| Net Income (Loss) Attributable to ParentJPY | 148,763,000Source | 115,404,000Source | 148,965,000Source | -990,731,000Source |
| Earnings Per Share, BasicJPY/shares | 29.13Source | 23.64Source | 30.54Source | -203.13Source |
| Earnings Per Share, DilutedJPY/shares | 28.52Source | 22.34Source | 27.23Source | -203.13Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 5,107,405Source | 4,882,501Source | 4,877,404Source | 4,877,404Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 5,851,516Source | 5,166,653Source | 5,470,654Source | 4,877,404Source |
| Interest Expense (non-operating)JPY | 49,745,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsJPY | 182,413,000Source | 145,555,000Source | 85,918,000Source | 45,780,000Source |
| Costs and ExpensesJPY | 8,317,236,000Source | 7,219,522,000Source | 6,857,090,000Source | 5,880,412,000Source |
| Current Income Tax Expense (Benefit)JPY | 98,228,000Source | 7,209,000Source | 30,809,000Source | 24,767,000Source |
| Depreciation, Depletion and Amortization, NonproductionJPY | 176,413,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxJPY | 18,121,000Source | 26,825,000Source | 14,830,000Source | 14,992,000Source |
| Goodwill, Impairment LossJPY | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitJPY | 2,246,285,000Source | — | — | — |
| Interest ExpenseJPY | — | 36,868,000Source | 9,800,000Source | 11,950,000Source |
| Investment Income, InterestJPY | 8,000Source | 1,111,000Source | 6,072,000Source | 839,000Source |
| Labor and Related ExpenseJPY | 718,456,000Source | — | — | — |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling InterestJPY | -10,572,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicJPY | — | — | 148,965,000Source | -990,731,000Source |
| Nonoperating Income (Expense)JPY | 65,815,000Source | 412,201,000Source | 82,807,000Source | 56,106,000Source |
| Operating Lease, ExpenseJPY | 89,120,000Source | — | — | — |
| Selling ExpenseJPY | 181,159,000Source | — | — | — |
Filing attachments
mrm-ex99_1.htm · 6-K · 2026-11-18
Exhibit 99.1 FOR IMMEDIATE RELEASE MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request TOKYO, Japan, November 18, 2026 - MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended D…
Read attachment ↗mrm-ex4_13.htm · 20-F · 2026-11-18
Exhibit 4.13 [English Translation] MONEY LOAN AGREEMENT MEDIROM Healthcare Technologies Inc. (the "Borrower") and Triple One Investment Limited Partnership (represented by its general partner, CARPE DIEM Inc.; the "Lender") hereby enter into this agreement (this "Agreement") with respect to a loan for consumption of money as follows. Article 1 (Purpose) The purpose of this Agreement is to set out the terms on which the Lender lends money to the Borrower, and the other rights and obligations…
Read attachment ↗mrm-ex4_14.htm · 20-F · 2026-11-18
Exhibit 4.14 [English Translation] SECURITY AGREEMENT MEDIROM Healthcare Technologies Inc. (the "Grantor") and Triple One Investment Limited Partnership (represented by its general partner, CARPE DIEM Inc.; the "Secured Party") hereby enter into this security agreement (this "Agreement") in order to secure the obligations of the Grantor under the money loan agreement entered into between the parties (the "Original Agreement"), as follows. Article 1 (Purpose) The purpose of this Agreement is…
Read attachment ↗mrm-ex4_15.htm · 20-F · 2026-11-18
Exhibit 4.15 [English Translation] AGREEMENT ON THE PURCHASE AND CANCELLATION (REDEMPTION PRIOR TO MATURITY) OF THE SECOND UNSECURED CONVERTIBLE-TYPE CORPORATE BONDS WITH SHARE OPTIONS MEDIROM Healthcare Technologies Inc. (the "Issuer") and Triple One Investment Limited Partnership (the "Bondholder") hereby agree as follows (this "Agreement") with respect to the purchase and cancellation (redemption prior to maturity) of all of the MEDIROM Healthcare Technologies Inc. Second Unsecured Conver…
Read attachment ↗mrm-ex4_16.htm · 20-F · 2026-11-18
Exhibit 4.16 [English Translation] SET-OFF AGREEMENT MEDIROM Healthcare Technologies Inc. ("Party A") and Triple One Investment Limited Partnership (represented by its general partner, CARPE DIEM Inc.; "Party B") hereby enter into this set-off agreement (this "Agreement") with respect to the Transaction under the Agreement on the Purchase and Cancellation (Redemption prior to Maturity) of the CBs and the Money Loan Agreement, as follows. Article 1 (Purpose) The purpose of this Agreement is,…
Read attachment ↗mrm-ex4_17.htm · 20-F · 2026-11-18
Exhibit 4.17 [English Translation] AGREEMENT ON THE AMENDMENT OF THE REPAYMENT DATE AND CERTAIN OTHER TERMS OF THE MONEY LOAN AGREEMENT Triple One Investment Limited Partnership (represented by its general partner, CARPE DIEM Inc.; hereinafter "Party A") and MEDIROM Healthcare Technologies Inc. (hereinafter "Party B") hereby agree as follows with respect to the amendment of the repayment date, the method of repayment of the principal, the interest rate and the timing of payment of interest …
Read attachment ↗